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Congenital perforin deficiency is considered a rare cause of human immunopathology and
immune dysregulation, and classically presents as a fatal illness early in infancy. How-
ever, we propose that a group of related disorders in which killer lymphocytes deliver
only partially active perforin or a reduced quantum of wild-type perforin to the immune
synapse should be considered part of an extended syndrome with overlapping but more
variable clinical features. Apart from the many rare mutations scattered over the coding
sequences, up to 10% of Caucasians carry the severely hypomorphic PRF1 allele C272>T
(leading to A91V mutation) and the overall prevalence of the homozygous state for A91V
is around 1 in 600 individuals. We therefore postulate that the partial loss of perforin func-
tion and its clinical consequences may be more common then currently suspected. An
acute clinical presentation is infrequent in A91V heterozygous individuals, but we postu-
late that the partial loss of perforin function may potentially be manifested in childhood or
early adulthood as “idiopathic” inflammatory disease, or through increased cancer sus-
ceptibility – either hematological malignancy or multiple, independent primary cancers.
We suggest the new term “perforinopathy” to signify the common functional endpoints
of all the known consequences of perforin deficiency and failure to deliver fully functional
perforin.
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INTRODUCTION
Perforin (PRF, encoded by the PRF1 gene) is a pore-forming toxin
(1, 2) stored in the secretory granules of cytotoxic T lympho-
cytes (CTLs) and natural killer (NK) cells (collectively known as
cytotoxic lymphocytes, CLs) (3). During an immune response,
CLs form an immune synapse (IS) with various types of antigen-
presenting cell, and release PRF and granzyme serine proteases
into the synaptic cleft (4). The extracellular milieu of the IS (high
calcium and neutral pH) promotes perforin membrane binding
and insertion culminating in pore formation (5, 6), an indispens-
able requirement for granzymes to enter the target cell cytoplasm
and trigger a multitude of cell death signaling pathways (7–12).
A SPECTRUM OF CLINICAL PRESENTATIONS REFLECTING
FUNCTIONAL PRF DEFICIENCY
It was first appreciated around the turn of this century that the
complete loss of perforin activity results in a fatal, autosomal
recessive immunoregulatory disorder of infancy (median age of
onset<12 months), familial hemophagocytic lymphohistiocytosis
(FHL) (13), which can be cured only by heterologous bone marrow
transplantation (14). The inability to clear antigen-presenting cells
by impaired CLs causes an uncontrolled activation and expansion
of CD4+ and CD8+ T cells that secrete high levels of interferon-
γ. This cytokine is central to disease pathogenesis, as it leads to
macrophage activation and secondarily to the overproduction of
pro-inflammatory cytokines by these cells. This in turn is mani-
fested clinically as intractable fever, liver and spleen enlargement,
and hemophagocytosis in the bone marrow and lymphoid organs,
leading to severe anemia and leukopenia (15). It is generally
thought that macrophage activation and infiltration in bone mar-
row leads to hemophagocytosis in FHL patients. Recently, it was
shown that interferon-γ specifically potentiated phagocytosis of
erythrocytes by macrophages, thus suggesting a key mechanism
for anemia in these patients (16). Variations in clinical presenta-
tion stem in part from the fact that there are up to five independent
genetic causes of primary FHL and related syndromes (4). Linkage
analyses have identified four genetic causes that account for 80–
90% of FHL, while a further locus mapping to Chr 9 is yet to be
defined (17). Inactivating perforin mutations are responsible for
approximately 50% of all cases (type 2 FHL, FHL2), while muta-
tions in three other genes, UNC13D, STX11, and STXBP2 (FHL3,
4, and 5 respectively) impair or ablate the delivery of perforin to
the IS (18–21). Thus, all the causes of FHL are causally linked by
the failure to deliver sufficient active perforin to the IS.
Natural killer cells (innate immunity) and CTLs (adaptive
immunity) were first recognized for their key role/s in the defense
against viruses; more recently these cells have also been appreci-
ated as being critical for immune surveillance against a variety of
malignancies, particularly those of hematopoietic origin (22, 23)
or of multiple cancers in the same individuals (24). Both these
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roles reflect the importance of perforin in initiating the apop-
tosis of dangerous cells, either those harboring an intracellular
pathogen, or possessing the potential for uninhibited growth and
spread, to the detriment of the host. Given this, it is perhaps sur-
prising that (infantile) FHL rarely presents with overwhelming
sepsis syndrome caused by viral infection (with the rare excep-
tions of persistent or fulminant Epstein–Barr virus infection) and
almost never with malignancy. Thus, most cases of FHL are not
manifested directly through the consequences of failed “target
cell death” but rather, indirectly, through an apparent skewing of
the immune response toward exaggerated cytokine secretion, the
second major type of effector function of CTL/NK cells.
Recent work on CTL/NK cells has highlighted their regula-
tion of various inflammatory pathways through their cross-talk
with other components of the immune system (25–27); the conse-
quent aberrations in inflammatory responses leading from failed
perforin production can occur in response to known human
pathogens, although a specific pathogen that triggers the onset
of FHL is rarely identified. These phenomena strongly indicate
that perforin and the pathways that synthesize and deliver it to
the IS play a more fundamental role in immune homeostasis,
centered more particularly on adaption of the neonate to the myr-
iad “non-pathogenic” antigenic stimuli he/she will encounter after
leaving the womb. In this context, we postulate it is the failure
to clear “constitutive” antigen-presenting cells through perforin-
dependent (largely granzyme-mediated) cell death that induces
the increased secretion of interferon-γ from the killer lympho-
cyte, in turn provoking severe dysregulation of pro-inflammatory
and chemokine cascades in by-stander cells. The molecular and
cellular mechanisms causally linking failed target cell apopto-
sis and the hypersecretion of interferon-γ are of fundamental
importance to the pathophysiology of perforinopathies, and ought
to be the focus of intensive research. The consequential effects
on macrophages, including secondary pro-inflammatory cytokine
secretion and grossly increased macrophage phagocytic activity
are the major manifestations of disease and are most marked
when perforin activity is completely abolished, but less so if
some residual perforin activity persists, for example due to inher-
itance of perforin missense mutation/s that are not completely
inactivating. This theme is taken up again below, as we believe
that the variable clinical presentations probably flow on from
this fact. While this paper focuses on perforin, it has also been
noted for some time that granzymes (for example, granzymes
A and M) can influence inflammatory pathways (25, 27), some-
times in a perforin-dependent manner, and at other times without
the need for perforin to be present. While the significance of
granzyme-mediated inflammatory pathways for human health
are yet to be defined and hyper- (or hypo-) inflammatory syn-
dromes are not yet described, future research should keep this
possibility in mind. This is particularly so because granzyme genes
can show considerable polymorphism, both in mice (28) and
humans (29).
On the basis that congenital defects in CTL/NK that influence
the secretion of active perforin may become clinically evident at
various stages of life, we would like to propose that this group
of disorders be considered as perforinopathies under three sub-
headings: acute, subacute, and chronic, depending on the stage of
disease onset (Table 1). As alluded to above, earlier presentations
tend to reflect cytokine-mediated immunopathology; later in life, a
patient may present more cryptically with relatively weaker inflam-
matory manifestations or none at all (Figure 1). We think it is quite
likely that clinicians managing these less urgent clinical presenta-
tions may not have previously considered perforinopathy in the
differential diagnosis, particularly in children presenting with a
variety of inflammatory disorders beyond infancy.
ACUTE PRESENTATIONS OF PERFORINOPATHY – FHL
For the purpose of this discussion, we define acute perforinopa-
thy as that resulting in a clinical presentation prior to the age of
24 months, with median of approximately 9 months (this may vary
depending on the genetic cause of FHL). As discussed above, the
pathogenesis involves a cascade of downstream events following
on from the inability of NK cells and CTL to present functional
perforin and, therefore, kill a cognate target cell. Affected infants
typically present with “classic” FHL and meet all or most of the
criteria described in HLH-2004 (15). The diagnosis is confirmed
by the loss of NK cytotoxicity (which is convenient to test, as
the NK cells of healthy individuals display constitutive, pathogen-
independent cytotoxicity) and identification of mutations in can-
didate genes (PRF1, UNC13D, STX11, STXBP2). Affected infants
are typically very unwell, and may require admission to a high-
dependency or intensive care unit; given the autosomal recessive
inheritance of most of these disorders, a sibling may have previ-
ously been similarly affected, while parents are almost always unaf-
fected carriers. Patients first have their condition stabilized, and are
then prepared for heterologous bone marrow transplantation, the
only potentially curative therapy (14, 15).
Acute perforinopathy is caused by detrimental mutations in
PRF1 or in proteins responsible for its delivery from the lumen
of cytotoxic granules to the IS, UNC13D, STX11, or STXBP2 (4).
The molecular basis of many disease-causing PRF1 mutations has
been investigated directly using recombinant expression systems
(23, 30–33), and is supported by the X-ray crystal structure of
perforin (1). In contrast, the biochemical bases of pathological
mutations in the other three proteins, Munc13-4, Syntaxin11, and
Munc18-2, remain largely unexplored due to the lack of suffi-
ciently informative experimental systems. As a result, the loss
of molecular function is predicted (34, 35), either on the basis
of undetectable NK cell activity and/or severely reduced protein
expression due to degradation. In the context of an early onset
FHL (acute perforinopathy), the known structural and cellular
defects correlate well with disease severity. Indeed, in the case of
PRF1, genuinely “null” mutations are most commonly caused by
nonsense or frame-shift mutations and in-frame deletions that
completely abrogate function. By contrast, a careful genotype-
phenotype analysis has revealed that only about 50% of missense
mutations ever reported resulted in a complete loss of perforin
function, either due to direct interference with a critical functional
domain or unscheduled post-translational modifications such as
glycosylation (30, 36). The remaining PRF1 missense mutations
were more commonly associated with atypical presentations of
FHL or with seemingly unrelated pathologies (immunoregula-
tory or otherwise) in older children, adolescents, and even adults,
who did not necessarily presented with FHL at all (23, 37). If
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Table 1 | Possible clinical manifestations of perforinopathy.
Acute perforinopathy Sub-acute perforinopathy Chronic perforinopathy
Age at onset 0–2 years >2 years Adolescents – adults
Cause Bi-allelic mutations in PRF1, UNC13D,
STX11, STXBP2, leading to complete
loss-of-function
Bi-allelic mutations in PRF1 and, putatively, in
UNC13D, STX11, STXBP2, leading to partial
loss-of-function
Monoallelic mutations in PRF1 [e.g.,
polymorphism 272C>T (Ala91Val)],
and possibly, other FHL-causing
genes, are contributing not
causative factors
Onset “Classical” FHL – meets all or most of
the criteria described in HLH-2004
Difficult to diagnose as does not meet minimal
essential criteria of HLH-2004: e.g., inflammatory
disease that responds to corticosteroid therapy and
has remitting/relapsing clinical course; hematological
malignancy
May include a range of conditions,
including hematological malignancy,
macrophage activation syndrome,
lymphoproliferative disease, but not
FHL
Diagnostic
features
Intractable fever and
hepatosplenomegaly are early and
prominent
Once FHL is suspected, conduct tests as described in
HLH-2004. Severe reduction of NK cell function that
prompts genetic analysis may indicate FHL. Test
siblings for bi-allelic mutations in FHL-related genes
Mild reduction of NK function. No
symptoms described in HLH-2004
are expected
Investigations (including NK function
assays) described in HLH-2004 will
strongly suggest FHL, and disease is
confirmed by DNA sequencing
Therapy Use protocols in HLH-2004;
heterologous stem cell transplantation
is the only curative therapy
Initially, corticosteroid therapy Disease-specific therapy, ranging
from corticosteroids to stem cell
transplantation
When genetic cause is identified, HLH-2004 and
heterologous stem cell transplantation, as the only
cure. If asymptomatic siblings are carriers of bi-allelic
mutations in FHL-related genes, preventative stem
cell transplantation may be considered
residual perforin activity delays the clinical onset beyond the age
of 12 months, we term the presentation “subacute.”
SUB-ACUTE PRESENTATIONS OF PERFORINOPATHY
Sub-acute perforinopathies have a wide spectrum of manifesta-
tions, all of which are all caused by a partial (“sub-total”) loss of
CL cytotoxicity due to bi-allelic mutations in one of the four genes
described above. Unlike the acute form of the disease, sub-acute
perforinopathies may be difficult to diagnose due to their generally
milder and more “patchy” clinical presentations, an intermittent
clinical course, a range of ages of onset and their frequent response
to non-specific immune-suppressive or immune-ablative thera-
pies (38, 39). These patients are more likely to present with a
precipitating infection or with an isolated inflammatory manifes-
tation such as pneumonitis that can lead the treating clinician
away from the underlying diagnosis. While the only curative
therapy for such patients is still ultimately bone marrow trans-
plantation, combination drug therapy may induce remissions of
variable duration. These non-curative interventions may be the
only available therapies that influence disease outcome, but they
have frequent unwanted effects such as opportunistic infection,
growth retardation, and bone marrow suppression. Alleviating
symptoms that might have categorized them as FHL patients
might also delay diagnosis in both the patient and their younger
FIGURE 1 | All of the clinical presentations of perforin deficiency
(including the failure to deliver active perforin into the immune
synapse) result from failed killing of an antigen-presenting cell. Early in
life, the clinical manifestations are more likely to reflect cytokine
hypersecretion due to chronic stimulation of CD4 and CD8 CTLs and NK
cells, resulting in disordered immune hemostasis affected both the
lymphoid and myeloid compartments. Later in life, hyper-inflammatory
presentations are less likely, and the clinical scenario is more likely to
reflect failure to clear dangerous target cells, particularly virus-infected cells
and neoplastic cells.
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siblings (38). Considering the fact that “classic” FHL is relatively
rare and commonly described in infants or very young children,
we believe sub-acute perforinopathies may be under-diagnosed,
and thus may delay consideration of curative stem cell transfer as
a definitive treatment option.
How common are sub-acute perforinopathies? The inevitable
answer is “We do not know.” Due to the lack of direct functional
data on Munc13-4, syntaxin 11, and Munc18-2 mutations, we will
discuss perforin deficiency as a paradigm for partial loss of CL
function. The first indication that bi-allelic perforin mutations
may lead to atypical FHL came from the observation that indi-
viduals who inherit two mutant alleles of PRF1, one of which
is the common polymorphism C272>T, encoding the ostensi-
bly conservative Ala91Val (A91V) substitution, presented at an
older age than “classic” FHL, and with variable symptoms (13,
38, 39). The initial suggestion that the “polymorphism” may be
pathogenic was initially met with skepticism, due largely to the
very high frequency of the allele among Caucasians (8–17% are
heterozygotes) and the rareness of early onset FHL, which was con-
sidered at that time to be the only authentic manifestation of the
disease (40). However, over the next several years, additional clin-
ical research and biochemical studies have confirmed the original
prediction that the A91V substitution is a genuine mutation that
impacts severely on perforin structure and function (31, 41). While
a prospective cohort study has never been reported, it is nonethe-
less clear from many reported case studies that inheritance of A91V
in the homozygous state or its co-inheritance with a genuinely
null allele is very strongly associated with atypical FHL or other
immunopathologies that are delayed compared with “classic” dis-
ease (sub-acute perforinopathies). In the largest epidemiological
studies reported to date [involving over 2,600 healthy individuals –
(42–44)], healthy A91V homozygotes have been reported only in
one study (42); every other reported case of A91V homozygocity
was invariably associated with a pathology. However, the statisti-
cal power of these studies linking the genotype with disease has
been insufficient to achieve significance. Based on the Mendelian
inheritance of perforin mutations, it is predicted that at least 1
in 600 Caucasian individuals should be homozygous for A91V.
Assuming strong penetrance of an associated immunopathology
in these individuals, such a perforinopathy would be almost 100
times as common as classic (“acute”) FHL. Remarkably, at this fre-
quency, A91V-related immune deficiency would rank among the
most common congenital disorders; it would be approximately
four times as frequent as cystic fibrosis and at a par with Down
syndrome.
Is partial perforin deficiency a common phenomenon, and is
it caused only by A91V? A retrospective analysis of all reported
cases of FHL associated with bi-allelic PRF1 mutations uncov-
ered a previously unappreciated dichotomy: half of the patients
who carried at least one missense mutation in PRF1 presented
“acutely,” with a FHL-like syndrome before the age of 12 months,
while the remaining 50% had significantly delayed FHL, or pre-
sented with other, seemingly unrelated pathologies (23, 37, 45).
Most of these patients either developed hematological malig-
nancies (usually beyond the age of 10 years, which we consider
to be a “chronic” presentation) or presented with unusual or
protracted viral infections (23, 46, 47). Critically, biochemical
analysis of multiple missense mutations associated with atypi-
cal FHL has led to the realization that partial perforin deficiency
results from perforin misfolding: all reported cases of atypical,
delayed FHL had some recoverable perforin-mediated cytotoxicity
in vitro (23). Structural studies recently supported these findings,
as wild-type perforin was shown to be a thermo-labile protein,
with a melting temperature (the temperature at which the pro-
tein denatures and starts to lose function) only slightly above
40°C (5). Even though this analysis was conducted in vitro, this
finding has raised the intriguing possibility that the protracted,
cytokine-induced fever of FHL might further aggravate the disease
by accentuating the protein misfolding defect. Given the diversity
of clinical presentation that encompasses cancer, atypical onset of
viral infections, and attenuated FHL-like syndromes, it is likely
that a significant proportion of sub-acute perforinopathies go
undiagnosed.
Identification of missense mutations that confer partial activ-
ity for the proteins encoded by the UNC13D, STX11, and STXBP2
genes may broaden the spectrum of recognized sub-acute per-
forinopathies. A number of non-synonymous polymorphisms in
these genes have already been cataloged in single nucleotide poly-
morphism (SNP) databases, and future studies will determine
whether any of these variations can affect the rate and/or efficiency
of secretory granule exocytosis and membrane fusion, steps that
ultimately determine the amount of perforin secreted into the IS
and its rate of delivery.
CHRONIC PRESENTATIONS OF PERFORINOPATHY
We consider chronic perforinopathies to be disease states that rep-
resent as a spectrum of immune-mediated diseases associated with
monoallelic mutations in FHL-related genes. The presentations
typically do not have a strong resemblance to classic FHL and
may include blood cancers and macrophage activation syndrome
in patients with juvenile rheumatoid arthritis. Typically, age of
onset will be beyond 5 years of age. In addition, some studies have
reported an association of PRF1 polymorphisms and the outcome
of allogeneic bone marrow transplantation. All of these associa-
tions are contentious, as studies that find no link outnumber those
supporting such an association.
Once again, the most reliable and “testable” information comes
from the analysis of PRF1 polymorphisms, as the functional con-
sequence of mutations is well understood. Considering the fact
that hundreds of FHL patients with known genetic defects have
been diagnosed around the world since 1999, the number of their
family members who are known carriers of monoallelic muta-
tions, should exceed 1,000. This is a significant cohort of unrelated
individuals, who may be potentially investigated in prospective
longitudinal studies on immune surveillance of infections and
cancer and for dysregulated immune homeostasis.
An association between presumed partial CL deficiency due
to monoallelic A91V perforin polymorphism, and acute lym-
phoblastic leukemia or macrophage activation syndrome, has been
demonstrated in several studies that have necessarily involved a
limited number of individuals (48, 49), but no statistical difference
was observed in follow up studies when larger cohorts of patients
were examined (24, 43). The likely reason for this apparent discrep-
ancy may be the relatively low statistical power of smaller studies.
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Another possibility is that a partial deficiency of CL function
may predispose more strongly to a specific subtype of malig-
nancy or other pathology. For example, while the largest analysis
of patents with acute lymphoblastic leukemia did not reveal an
enrichment of A91V carriers compared to healthy controls, a sub-
set of the ALL patients who also had BCR-ABL translocations
were more likely to carry the A91V allele than the control group
(43). Similarly, in a study that retrospectively examined patients
who had been diagnosed with more than one primary malignancy
during their lifetime, a significant proportion of patients diag-
nosed with both melanoma and B cell lymphoma were carriers
of A91V or another perforin mutation that is partly inactivating
(R28C), than those who had been diagnosed with either disease
alone (24).
We have tried to explore the molecular basis for how a monoal-
lelic mutation might adversely affect overall cytotoxic function
in an inherited condition classically considered to be recessive.
Molecular analysis has revealed that A91V has a partial dominant-
negative effect on the function of wild-type perforin; partly mis-
folded perforin might interfere with the expression or trafficking
of normal perforin through the endoplasmic reticulum/Golgi to
the secretory granules (31, 50). Once wild-type and misfolded
perforin molecules are “mixed” and stored together, it is easy
to imagine that perforin pores with a heterogeneous composi-
tion of monomers might have disproportionately poor function.
We also speculate that in heterozygous individuals, the wild-type
allele may be under-expressed relative to the mutated allele, thus
further diminishing overall CL function. This possibility needs
to be formally excluded, but has been described for many other
polymorphic genes [e.g., Ref. (51)].
Further analysis of CL function in patients with immune-
mediated disease is warranted, particularly employing recent
advances in single-cell microscopy technology, which may reveal
CL deficiencies that would otherwise remain undetected in cell
population-based experiments (6). Such technologies may vali-
date the more common statistical approaches, where for example,
the frequency of a PRF1 mutation in cancer patients is com-
pared to that in healthy controls. In acute perforinopathy, there
is a clear causal relationship between the disease phenotype and
the patient’s genotype, but this is not the case in cancer (even
assuming a clinician considered testing for perforin genotype,
which would be unusual). Rather, most chronic perforinopathies
are likely to present “indirectly.” In cancer, the PRF1 gene [and,
most likely, UNC13D, STX11, and STXBP2 (52)] would be con-
sidered to be a tumor suppressor gene, but is not the cause
of malignancy per se and is certainly not the only causal fac-
tor. Rather, impaired perforin function reduces the surveillance
of cancerous cells, which were generated through an unrelated
genetic event. This notion raises a question of what constitutes
an appropriate control in these studies. Since the hypothesis is
that carriers of monoallelic mutation(s) in PRF1 or related genes
predispose to immune-mediated diseases with uncertain age of
onset, taking a “snapshot” of a healthy population may under-
estimate the impact of mutations. In contrast, it was recently
shown that individual differences between the cytotoxic activity
of NK cells (and cytotoxic T cells) are much smaller than pre-
viously thought (6). This opens an avenue for “personalized”
analysis of CL function that may shed light on predisposition
of an individual to an immune pathology, prospectively and
retrospectively.
SUMMARY
In this discourse, we have proposed the term “perforinopathy”
to denote the wide and diverse spectrum of manifestations of
perforin deficiency, both temporal and clinical. Early (acute)
clinical presentations are often fatal and usually represent dys-
regulated immune homeostasis and the resultant hypercytokine-
mia (“cytokine storm”) and hemophagocytosis consequent on
macrophage activation. Sub-acute presentations still occur in
infancy/early childhood, may typically have a more benign course
that is still principally inflammatory and may accompany other
pathologies such as juvenile idiopathic arthritis or virus infection.
Chronic manifestations of perforin deficiency may appear as late
as adulthood, and the principal cause of symptoms is the failure
to clear specific dangerous cells, particularly pre-malignant cells.
Hematopoietic malignancies seem to be a common outcome, and
some patients may present well into adulthood with more than one
primary cancer: early onset malignant melanoma and lymphoma
is the commonest combination we have observed. Although most
of the data supporting our proposed “classification” is centered on
our knowledge of PRF1 gene mutations, we hope that this paper
will stimulate further study on polymorphisms and mutations of
other genes that play a role in delivering functional perforin to the
target cell.
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